Skip to main
  1. Stocks
  2. Spectral AI Inc
  3. Forecast
MDAI

MDAI Stock Forecast & Price Target

MDAI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Spectral AI is supported by a differentiated AI-enabled diagnostic platform that can objectively and immediately assess wound healing potential, with clinical studies showing improved efficiency and a large, under-penetrated advanced wound care market to address. FDA clearance for DeepView System for Burn Centers, Trauma Centers, and Emergency Departments de-risks commercialization, while BARDA’s ~$31.7M funding and support for ~30 systems, plus potential subsidy for ~140 more, strengthen early adoption and non-dilutive growth. Its license model could support recurring, high-margin revenue, and the ~125 burn centers and ~5,000 trauma and ED units in the US underscore a sizable ~$3.7B TAM with further upside from DeepView SnapShot M and future indications.

Bears say

Spectral AI is viewed negatively because its investment case remains highly dependent on a commercial launch of DeepView that has not yet been proven, while projected FY26-FY30 revenue growth of 110% CAGR rests on an aggressive adoption and reimbursement backdrop. The company’s estimated 2030 revenue of $18.5M and 5.5x NTM EV/Sales multiple also imply a valuation that is vulnerable if clinical and regulatory timelines slip or BARDA-related revenue comes in lower than expected. Its limited operating history, competition, cybersecurity risk, and potential need for additional capital further weaken the fundamental risk-reward profile.

MDAI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Spectral AI Inc and is not a guaranteed prediction by Public.com or investment advice.

MDAI Analyst Forecast & Price Prediction

Get the latest MDAI stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MDAI

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Spectral AI Inc (MDAI) Forecast

Analysts have given MDAI a Strong Buy based on their latest research and market trends.

According to 1 analysts, MDAI has a Strong Buy consensus rating as of Oct 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Spectral AI Inc (MDAI)


MDAI Analyst Forecast & Price Prediction

Get the latest MDAI stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MDAI

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MDAI stock data and trends